46% of US dermatologists expect to prescribe Pfizer's tofacitinib to psoriasis patients who failed one biologic

In the first year following its approval for psoriasis, nearly one-half (46%) of surveyed dermatologists in the USA expect to prescribe Pfizer’s janus kinase inhibitor tofacitinib (prposed trade name Janus) to patients who have failed one biologic, says advisory firm Decision Resources.

38% of surveyed dermatologists anticipate using the drug for patients who have been previously treated with one oral agent and are biologic-naive. On average, surveyed dermatologists who expect to prescribe tofacitinib estimate that 35% of psoriasis patients who initiate tofacitinib by year-end 2014 will have previously received one or more conventional oral agents and will be naive to biologics.

Views on Celgene’s apremilast